منابع مشابه
Tedizolid Phosphate (Sivextro)
INTRODUCTION Between 2001 and 2003, acute bacterial skin and skin structure infections (ABSSSIs) accounted for more than 11 million ambulatory care visits, with a visit rate of 410.7 per 10,000 persons.1 As a broader term, ABSSSI encompasses the following (Table 1):2–4 1. Cellulitis/erysipelas 2. Wound infection 3. Major cutaneous abscess This infection is characteristically identifi ed by a me...
متن کاملDalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
Antibacterial agents Skin and skin structure infections are most often caused by Grampositive bacteria such as streptococci and staphylococci. The number of these infections that are caused by methicillin-resistant Staphylococcus aureus (MRSA) has rapidly increased in recent years in both the community and hospital settings. MRSA skin infections experienced in the community can usually be effec...
متن کاملTedizolid Phosphate: a Next-Generation Oxazolidinone
Treatment of multidrug-resistant Gram-positive infections continues to challenge clinicians as the emergence of new resistance mechanisms outpaces introduction of novel antimicrobial agents. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus spp. Tedizolid has consistently shown pote...
متن کاملStability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration
Tedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infections. To determine whether the expected dose of tedizolid phosphate can be delivered via nasogastric tube in patients who have difficulty swallowing and in whom venous access is not suitable, this in vitro study evaluated the recovery of tedizolid phosphate 200-mg tablets after crushing, dispersio...
متن کاملTedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
The novel oxazolidinone tedizolid phosphate is in late-stage development for acute bacterial skin and skin structure infections (ABSSSIs). Preclinical and phase 1 trials have shown that 200-mg once-daily tedizolid phosphate dosing achieves the appropriate pharmacokinetic goals for optimal antimicrobial effect, and a randomized phase 2 dose-ranging trial confirmed that tedizolid phosphate may be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hospital Pharmacy
سال: 2014
ISSN: 0018-5787,1945-1253
DOI: 10.1310/hpj4910-961